BPX-601

BIOLOGICAL2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Metastatic Castration-resistant Prostate CancerMetastatic Prostate CancerProstate Cancer

Phase 1

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

TerminatedNCT02744287

Regeneron PharmaceuticalsMetastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer

Start: 2016-11-30End: 2023-03-14Updated: 2026-02-23

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

RecruitingNCT07543055

Regeneron PharmaceuticalsProstate Cancer

Start: 2026-09-10End: 2031-06-27Target: 36Updated: 2026-08-28

Related Papers

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.

2024-12-3021 citations

Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2023-02-2012 citations

Tumor infiltration and cytokine biomarkers of prostate stem cell antigen (PSCA)-directed GOCAR-T cells in patients with advanced pancreatic tumors.

Journal of Clinical Oncology2020-02-015 citations

Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results with cyclophosphamide (Cy) ± fludarabine (Flu) lymphodepletion (LD).

Journal of Clinical Oncology2019-05-2022 citations

Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results from a dose escalation.

Journal of Clinical Oncology2019-01-2913 citations

Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T™ cells in advanced solid tumors: Preliminary results from a dose escalation study

Annals of Oncology2018-12-013 citations